Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2007 1
2008 1
2010 2
2011 2
2012 1
2013 2
2014 1
2015 1
2017 2
2018 2
2019 2
2020 1
2021 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
MEK/ERK addiction in CNL/aCML.
Kesarwani M, Kincaid Z, Azam M. Kesarwani M, et al. Oncotarget. 2017 Nov 3;8(59):99215-99216. doi: 10.18632/oncotarget.22283. eCollection 2017 Nov 21. Oncotarget. 2017. PMID: 29245892 Free PMC article. No abstract available.
MAPK-negative feedback regulation confers dependence to JAK2V617F signaling.
Kesarwani M, Kincaid Z, Azhar M, Menke J, Schwieterman J, Ansari S, Reaves A, Deininger ME, Levine R, Grimes HL, Azam M. Kesarwani M, et al. Leukemia. 2023 Aug;37(8):1686-1697. doi: 10.1038/s41375-023-01959-0. Epub 2023 Jul 10. Leukemia. 2023. PMID: 37430058 Free PMC article.
Momelotinib is a highly potent inhibitor of FLT3-mutant AML.
Azhar M, Kincaid Z, Kesarwani M, Ahmed A, Wunderlich M, Latif T, Starczynowski D, Azam M. Azhar M, et al. Among authors: kesarwani m. Blood Adv. 2022 Feb 22;6(4):1186-1192. doi: 10.1182/bloodadvances.2021004611. Blood Adv. 2022. PMID: 34768286 Free PMC article.
Adaptive responses to mTOR gene targeting in hematopoietic stem cells reveal a proliferative mechanism evasive to mTOR inhibition.
Fan C, Zhao C, Zhang F, Kesarwani M, Tu Z, Cai X, Davis AK, Xu L, Hochstetler CL, Chen X, Guo F, Huang G, Azam M, Tian W, Lu QR, Zheng Y. Fan C, et al. Among authors: kesarwani m. Proc Natl Acad Sci U S A. 2021 Jan 5;118(1):e2020102118. doi: 10.1073/pnas.2020102118. Epub 2020 Dec 21. Proc Natl Acad Sci U S A. 2021. PMID: 33443202 Free PMC article.
Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML.
Azhar M, Kincaid Z, Kesarwani M, Menke J, Schwieterman J, Ansari S, Reaves A, Ahmed A, Shehzad R, Khan A, Syed N, Amir N, Wunderlich M, Latif T, Seibel W, Azam M. Azhar M, et al. Among authors: kesarwani m. Blood Adv. 2023 Apr 25;7(8):1460-1476. doi: 10.1182/bloodadvances.2022007486. Blood Adv. 2023. PMID: 36044389 Free PMC article.
The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes.
Lin P, Ren Y, Yan X, Luo Y, Zhang H, Kesarwani M, Bu J, Zhan D, Zhou Y, Tang Y, Zhu S, Xu W, Zhou X, Mei C, Ma L, Ye L, Hu C, Azam M, Ding W, Jin J, Huang G, Tong H. Lin P, et al. Among authors: kesarwani m. Haematologica. 2019 Mar;104(3):485-496. doi: 10.3324/haematol.2018.197749. Epub 2018 Sep 27. Haematologica. 2019. PMID: 30262569 Free PMC article.
22 results